Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AUR103 + rituximab
- Development stage
- Unknown
- Lead developer
- Aurigene Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AUR103 + rituximab is an investigational combination therapy under clinical evaluation for the treatment of non-Hodgkin lymphoma (NHL). AUR103, developed as the calcium salt formulation ("AUR103 Calcium"), is an orally administered small molecule; its precise molecular target/mechanism has not been explicitly disclosed in public registries, but it is being studied for use in advanced malignancies. In combination with rituximab, a monoclonal antibody targeting CD20 on B-cells, the regimen is intended to enhance antitumor activity against relapsed or refractory NHL. The combination is currently being assessed in a Phase I study to evaluate safety, pharmacokinetics, and preliminary efficacy in this population[1][7].
02
Targets
Beyond the preview
Go deeper on AUR103 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AUR103 + rituximab.